Literature DB >> 12043184

[Biclonal light chain gammopathy in multiple myeloma--a case report].

Toshie Ogasawara1, Masako Yasuyama, Kiyotaka Kawauchi.   

Abstract

A 74-year-old woman was admitted to our hospital in March 1998 for low-back pain. In 1990, she had a chemotherapy for diffuse mixed cell lymphoma. Biochemical and serologic assays revealed a total protein level of 9.7 g/dl and an IgG level of 4,530 mg/dl. Immunoelectrophoresis showed monoclonal IgG protein associated with two monoclonal kappa and lambda light chain components. Bone marrow examination showed proliferation of myeloma cells comprising up to 25% of all nucleated cells. Myeloma cells were immunohistochemically positive for IgG and kappa and lambda light chains. IgG contained equal amounts of IgG 1 and IgG 2 subtypes and the complementarity determining region 3 (CDR 3) of myeloma cells showed oligoclonality by polymerase chain reaction, suggesting the myeloma cells may have two components. The patient received melphalan and prednisone in combination, resulting in only a minor response. She eventually developed angioimmunoblastic T-cell lymphoma. Biclonal gammopathy associated with malignant lymphoma is rare in case of multiple myeloma and may provide some insight into the pathogenesis of plasma cell tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12043184     DOI: 10.2177/jsci.25.170

Source DB:  PubMed          Journal:  Nihon Rinsho Meneki Gakkai Kaishi        ISSN: 0911-4300


  2 in total

1.  Non-secretory immunoglobulin E myeloma associated with immunoglobulin G monoclonal gammopathy of undetermined significance.

Authors:  Masako Yasuyama; Toshie Ogasawara; Kuniaki Otsuka; Motohiko Aiba; Kiyotaka Kawauchi
Journal:  Hematol Rep       Date:  2012-07-02

2.  Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report.

Authors:  Ho Sup Lee; Lee Chun Park; Seong Hoon Shin; Sang Uk Lee; Hee Kyung Chang; Bang Huh; Gyoo Sik Jung; Mi Hyang Kim; Yang Soo Kim
Journal:  Cancer Res Treat       Date:  2011-09-30       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.